The HER-2/neu on~cne is a member of the erbB-likc oncogene family, and ts related to, but distinct from, the epidermal growth factor .reccptoc. This gene has been shown to be amplified in human breast cancer cdl lines.
In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2-to greater than 20- fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/IU'# gene was a significant predictor of both overall survival and time to -~psc in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/nn amplification had greater prognostic value than most currently used rn?SDostic factors, including hormonal-receptor status, m lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
T HB BVIDENCE LINKING PROTO-ONCOGENES TO THE INDUC-
tion or maintenance of human malignancies is largely circumstantial, but has become increasingly compelling. This circumstantial evidence is derived from studies of animal models, tumor cell lines, and actual human tumors. Data from animal models and cell lines include: (i) sequence homology between human protooncogenes and the viral oncogenes of transforming retroviruses that arc known to be tumorigcnic in some species (1, 2); (ii) ttansfcction studies showing the tranSforming potential of proro-onoogcnes in NIH 3T3 cells and primary embryo fibroblasts (3) (4) (5) ; and (iii) the central role of certain proto-oncogenes in tumorigenesis by chronic transforming retroviruses such as avian lcuk~is virus (6) . Data from human tumors include: (i) increased expression of specific protooncogcnes in some human malignancies (7, 8) ; (ii) localization of proto-oncogcnes at or near the site of specific, tumor-associated chromosomal ttanslocations (9) ; and (iii) amplification of protooncogcnes in some human tumors (10, 11) .
Additional data linking proto-oncogcnes to cell growth is their expression in response to certain proliferation signals (12, 13) and their expression during embryonic development (14, 15) . More direct evidence comes from the fact that, of the 20 known protooncogenes, three arc related to a growth factor or a growth factor receptor. These genes include c-sis, which is homologous to the 9 JANUARY 1987 transforming gene of the simian sarcoma virus and is the ~ chain of platelet-derived growth factor (PDGF) (16, 17) ; c-ftn.s, which is homologous to the transfurming gene of the feline sarcoma virus and is cl~y related to the macrophage colony-stimulating factor receptor (CSF-lR) (18) ; and c-erbB, which encodes the EGF receptor (EGFR) and is highly homologous to the transforming gene of the avian crythroblastosis virus (19) . The two rcccptorrelated proto-oncogcnes, c-ftn.s and c-erbB, arc members of the tyrosine-specific protein kinase f;unily to which many proto-oncogcnes belong.
Recently, a novel transforming gene was identified as a result of transfcction studies with DNA from chemically induced rat ncuroglioblastomas (20) . This gene, called neu, was shown to be related to, but distinct from, the c-erbB proto-oncogcnc (21) . By means of v-erbB and human EGFR as probes to screen human genomic and complementary DNA (cDNA) libraries, two other groups independently isolated human erbB-related genes that they cal.led HER-2 (22) and c-erbB-2 (23) . Subsequent sequence analysis and chromosomal mapping studies revealed all three genes (neu, c-erbB-2, and HER-2) to be the same (22, 24, 25) . A fourth group, also using verbB as a prob;c, identified the same gene in a mammary carcinoma cell line, MAC 117, where it was found to be amplified five-to tenfold (26) .
This gene, which we will call HER-2/neu, encodes a new member of the tyrosine kinase family; and is cl~y related to, but distinct from, the EGFR gene (22). HER-2/neu differs from EGFR in that it is found on band q21 of chromosome 17 (22, 24, 25) , as compared to band pll-pl3 of chromosome 7, where the EGFR gene is located (27) . Also, the HER-2/neu gene generates a messenger RNA (mRNA) of 4.8 kb (22), which differs from the 5.8-and 10-kb transcripts for the EGFR gene (28) . Finally, the protein encoded by the HER-2/neu gene is 185,000 daltons (21) , as compared to the 170,000-dalton protein encoded by the EGFR gene. Conversely, on the basis of sequence data, HER-2/neu is more closely related to the EGFR gene than to other members of the tyrosine kinase family (22). Like the EGFR protein, HER-2/neu has an extracellular domain, a ttansmembranc domain that includes two cystcine-rich repeat clusters, and an intracellular kinase domain (21) , indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.
As a result of the published data showing amplification ofHER-2/'le# in .a human mammary carcinoma cell line, and as part of an ongoing survey in our laboratory of proto-oncogcnc abnormalities in human tumors, we evaluated altcratiom of the HER-2/nn1 gene in a large series of human primary breast cancers. Our results show that amplification of this gene occurs rclativcly frequently in breast cancer, and that it is associated with disease relapse and overall patient survival.
Factors that arc known to be important in the prognosis of breast malignancies in individual patients include: size of the primary tumor, stage of disease at diagnosis, hormonal receptor status, and number of axillary lymph nodes involved with disease (~itivc nodes) (29) . The current study, which was conducted in two parts, involved the evaluation of tissue from 189 separate breast malignan· cies that were part of a breast cancer study ongoing at the University of Texas, San Antonio. This cohort of tumors was of inttrcst because considerable infOrmation was available on the majority of the specimens including size of the primary tumor, estrogen receptor status, progesterone receptor status, age of patient, disease stage, and status of the axillary lymph nodes.
In the initial survey, tissue from 103 primary breast cancers was evaluated for alterations in the HER-2/nn1 gene. DNA froni individual tumors was prepared as dcacribcd (30) , digested with Eco RI, and subjected to Southern blot analysis with a 32 P-labcled HER-2/11eU-l probe, which is known to detect a 13-kb hybridizing band in human DNA (22). Examples of tumors from the initial survey arc shown in Fig. 1 . Of the 103 samples c:xamincd, 19 (18'6) showed evidence of HER-2/nn1 gene amplification. The dcgrcc of amplification in individual cases was dctcnnincd by dilution analysis ( Fig. 2A) , as well as soft laser densitometry scanning. To dctcnn.inc that the amount of DNA loaded in each Jane was equivalent, all filters were washed and rchybridizcd with a "P-labclcd argin.asc gene probe (31 ) . This probe identifies a 15-kb hybridWng band on Eco RI-digested human DNA, and was selected as a control because it more appropriately assesses the rclative amount and (Fig. 1) . The filter was first snipped of label by washing in a buffer made up of 50% Wnnamidc, 3x SSC, and 0.1% SDS at 65"°C for 20 minutes, following by three successive washes of 5 minutes each in 0.1 x SSC at room temperature. Filters were exposed overnight on XAR-5 film (Kodak) to ensure rcmov;d of all radioactive probe, then rchybridiud as in Fig. 1 with a 32 P-labclcd human arginasc gene probe (31) .
in a blinded fashion, in that they were made without knowledge of disease parameters. Analysis of the data for association bctwccn gene amplification and a number of disease parameters was then performed.
Of 103 tumors evaluated in the initial survey, there was essentially no correlation between gene amplification and estrogen receptor status, progesterone rcccptor status, size of tumors, or age at diagno,,is (Table 1) . However, when analysis was pcrfonned for asscxiation between HER-2/nn amplification and number of posi· rive lymph nodes, a trend was noted. 'This analysis showed that 4/34 (1196) of patients with no involved nodes, 1/20 (10%) with l to 3 involved nodes, and 8125 (3296) with >3 involved nodes had gene amplification (P = 0.11). If these data were examined by comparing 0 to 3 positive nodes versus > 3 positive nodes, the correlation with gene amplification became more significant (P < 0.05). Thus, there was a significant increase in incidence of HER-2/nn gene amplification in patients with > 3 axillary lymph nodes involved with disease. A multivariate regression analysis to correlate HER-2/nn amplification with various disease parameters identified the number of positive nodes as the only significant factor, either alone or in combination, to correlate with amplification.
This initial study indieatcd that it might be possible to discriminate among node-positive patients on the basis ofHER-2/nn gene (Fig. 1) . Amplification was found in 34186 (4096) of these patients. For this larger sample of node-positive patients, several statistically significant or nearly significant relationships were observed. In agrccmcnt with the preliminary swvey, there was an association between number of involved lymph nodes and HER· 21 nn amplification (Table 2 ). In addition, the presence of gene amplification was corrclatcd with estrogen receptor status and siz.c of primary tumor (Table 2) . Together, these two swvcys yielded data on 189 patients and the association of HER·2/nn amplification with various disease parameters in the combined group is shown in Table 3 .
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While these correlations were of interest, the strong relationship and local radiation alone, 17%. A sttong and highly statistically significant correlation was round between the dcgrcc of gene amplification and both time to disease relapse (P = <0.0001) and survival (P = 0.0011) ( Table 4) . Moreover, when compared in univariate analyses to other parameters, amplification ofHER-2/neu was found to be superior to all other prognostic factors, with the exception of the number of positive nodes (which it equaled) in predicting time to relapse and overall survival in human breast cancer ( Table 4 ). The association between HER-2/neu amplification and relapse and survival can be illustrated graphically in actuarial survival curves (Fig. 3 , A to D). While there was a somewhat shortened time to relapse and shorter overall survival .in patients having any amplification of the HER-2/neu gene in their tumors (Fig. 3, A and B) , the greatest diffcrcnccs were found when comparing patients with > 5 copies of the gene to those without amplification (single copy) (Fig. 3, C 
and D). Patients with greater
than five copies ofHER-2/neu had even shorter disease-free survival times (P = 0.015) and overall survival times (P"" 0.06) when compared to patients with no amplification. The phenomenon of greater gene copy number correlating with a worse prognosis has also been seen in evaluations of N-myc gene amplification in human neuroblastomas (32) .
To determine if amplification ofHER-2/neu was independent of other known prognostic factors in pttdicting disease behavior, multivariate survival analyses were pcrfonncd on the 86 nodepositive cases. Amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these (Fig. 1 ) patients, even when other prognostic factors were ta.ken into account ( Table 4) .
Rearrangement of the HER-2/neu gene was rare. Of the total 189 tumors evaluated, three showed evidence of rcarrangcincnt, and in two of the three cases, the rearrangement was identical (Fig. 1, cases  77 to 79) . Also, two of the rearranged HER-2/neu loci were amplified (Fig. 1, cases 78 and 79) . The incidence of HER-2/neu rcarrangcmcnt as determined by Eco RI digestion was too small to attempt statistical correlations.
To determine whether the phenomenon of amplification ofHER-2/neu in breast cane.er extended to related growth factor receptors, all filters were analyud with the EGFR probe (Fig. 4) . Amplification of the EGFR gene was found in 41189 (2%) of the cases, and rearrangement of the EGFR gene was found in one of those four cases. The incidence of EGFR amplification and rearrangement was too small to attempt statistical correlation. Comparison of HER-2/ MN amplification (53/189 or 28%) with that of the EGFR gene reveals the incidence of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase-specific receptor in human breast cancer. Moreover, studies examining alterations of two other tyrosine kinase-specific proto-oncogcnes, 1111' and fas, in breast cancer did not show amplification of these genes (33 ) .
Alterations of non-tyrosine kin~lated proto-oncogcnes in these indicate an association with disease behavior. The exact role of various proto-oncogcncs in the pathogenesis of human malignancies remains unclear. One line of evidcacc implicating abnormalities of these genes in human disca.sc is association of their amplification with nunor progression in specific cancers. The N-"'J' gene is frcquendy amplified in human ncuroblastomas and ncuroblastoma cell lines (35, 36) . Srudies on the N-mye protooncogcnc were the first to show a direct association between abnormalities in a proto-onc:ogcnc and clinical behavior of a human twn0r. N·myc amplitication and aprcssioo rorrelatc both with stage of disease and overall survival in patients with ncuroblastoma (IO, 32, 37) . Moreover the greater the N-"'J' gene copy number, the worse the patient prognosis for all stages of the disease (32) . Taken together, these data indicate a role for the N-myc gene in the pathogenesis of ncuroblastoma (32) .
Ncuroblastoma is a relatively rare disease with an incidence of one per 125,000 children. Carcinoma of the breast, however, is a common malignancy affecting one of every 13 women in the United States. There arc 119,000 new cases per year, and approximately 40,000 women will die of the disease in 1986 (38). Current trcaancnt decisions for individual patients arc frcquendy based on specific prognostic parameters. The major prognostic factors for breast cancer include presence· or absence of tumor in the axillaiy nodes, size of the primary rumor, and prcscncc or absence of hormonal receptors (29) . The current study indicates that amplification of the HER· 2/neu gene is a significant predictor of both overall survival and time to relapse in node-positive patients with breast cancer. Amplification of the gene retains its prognostic significance in multivariate analysis, even when adjusancnts arc made for other known prognostic factors. Moreover, amplification of HER-2/nn1 has greater prognostic value than most currcndy used prognostic factors, including progesterone and estrogen receptors, and is equivalent to and independent of the best known prognosticatornumber of positive lymph nodes. Finally, the dcgrcc ofHER-2/nn1 amplification appears to have an dfcct on survival, with greater copy number being associated with a worse prognosis (Fig. 3, C and D) . A similar phenomenon has been observed for N-"'J' gene amplification in human neuroblastoma (32) .
The potential role of HER-2/nn1 in the pathogenesis of breast cancer is wllmown. Like N-myc, the correlation of HER-2/neu amplification with disease progression indicates it may be an important gene in the disease process. The role of other cell 9 JANUARY 1987 receptors in the biology of breast cancer is well established (29, 39, 40) . It is easy to speculate that a gene encoding a putative growth factor receptor, when expressed in inappropriate amounts, may give a growth advantage to the cells expressing it. Alternatively, alteration in the gene product itself may lead to a critical change in the. receptor protein. A single point mutation in the transmcmbrane domain of the protein encoded by the rat neu oncogene appears to be all that is ncccssary for the gene to gain transforming ability (41) . Whether this or a similar alteration is found in the amplified HER-2/neu gene in human breast cancer will require sequence analysis of the homologous region in the amplified human gene. In addition, studies evaluating the expression of this gene at the RNA and/or protein level will prove important in dctcnnining if HER-2/neu amplification results in an cxpcctcd increased gene expression. The question of amplification of HER-2/neu in metastatic as compared to primary lesions in a given patient is important. The current study utiliu:d only primary breast tumors for analyses. It would be of interest to determine if HER-2/neu copy number is altered as the twnor mcwwizcs. A recent study evaluating N-myc copy nwnber in human small cell carcinoma of the lung showed no di.ffcrcncc between primary and metastatic lesions (11) .
1bc initial survey from the current study showed that 15% of breast cancer patients with stage I disease (node-negative) have HER-2/neu amplification. Unfortunately, no long-tenn follow-up data were available for these patients. This stage I setting may be an additional group in which HER-2/neu mcasurcrnents will have an impact in predicting biologic behavior of the tumor, and as a result, in design of tteaancnt strategy. Finally, if the HER-2/neu gene product functions as a growth factor receptor that plays a role in the pathogenesis of breast cancer, identification of its ligand and development of specific antagonists could have important therapeu· tic implications. and ddetiom, mostly in VPl, radically alter the surface features. In particular, the putative receptor binding "canyon" of human rhinovirus 14 becomes a deep "pit" in Mmgo virus because of polypeptide insertions in VPl that fill part of the canyon. The minor ca.psid peptide, VP4, is complctcly internal in M~ ~ but its association with the other capsid protelllB is substantially different from that in rhino-or poliovirus. However, its carboxyl terminus is located at a rcmtion similar to that in human rbinovirus 14 and polio~ suggesting the same autocatalytic cleavage ofVPO to VP4 and VP2 tam pJace during assembly in all these picomaviruses. each composed of a single copy ofVPl, VP2, VP3, and VP4 ( Fig.  1) with approximate relative molecular masses of 34,000, 30,000, 25,000, and 7,000 daltons, respectively. For Mengo virus, the proteins consist of277, 256, 231, and 70 amino acids, respectively. On degrading Mengo virus, the virions separate into 13.4S pcntamcrs.and then into 6S protomcrs (3, 4) consistent with structural observations (5) . Traditionally, the cardiovirus capsid proteins have been designated a, p, -y, and 8 in order of decreasing siu; the VPl 
